Efficacy of an Experimental Azithromycin Cream for Prophylaxis of Tick-Transmitted Lyme Disease Spirochete Infection in a Murine Model

Piesman, Joseph; Hojgaard, Andrias; Ullmann, Amy J.; Dolan, Marc C.

doi:10.1128/aac.01932-13

Cited by 15 publications

(9 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common routes of antibiotic administration are oral administration and intravenous injection. As an alternative approach, the topical application of 4% azithromycin cream was tested (Piesman et al 2014). The result of the study showed that azithromycin was highly efficient when applied topically at the sites of tick bites in mice (Piesman et al 2014).…”

Section: On-demand Treatment Strategiesmentioning

confidence: 99%

Novel targets and strategies to combat borreliosis

Strnad

Grubhoffer

Rego

2020

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Lyme borreliosis is a bacterial infection that can be spread to humans by infected ticks and may severely affect many organs and tissues. Nearly four decades have elapsed since the discovery of the disease agent called Borrelia burgdorferi. Although there is a plethora of knowledge on the infectious agent and thousands of scientific publications, an effective way on how to combat and prevent Lyme borreliosis has not been found yet. There is no vaccine for humans available, and only one active vaccine program in clinical development is currently running. A spirited search for possible disease interventions is of high public interest as surveillance data indicates that the number of cases of Lyme borreliosis is steadily increasing in Europe and North America. This review provides a condensed digest of the history of vaccine development up to new promising vaccine candidates and strategies that are targeted against Lyme borreliosis, including elements of the tick vector, the reservoir hosts, and the Borrelia pathogen itself.

show abstract

Section: On-demand Treatment Strategiesmentioning

confidence: 99%

Novel targets and strategies to combat borreliosis

Strnad

Grubhoffer

Rego

2020

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

show abstract

“…10 Azithromycin is a potential antibiotic agent for prophylactic topical use. 47,48,49 Guidelines are conflicting. CDC 8 recommends according to the Infectious Disease Society of America (IDSA) guidelines for the treatment of Lyme disease.…”

Section: Conflictingmentioning

confidence: 99%

The Controversies, Challenges and Complexities of Lyme Disease: A Narrative Review

Hout

2018

J Pharm Pharm Sci

View full text Add to dashboard Cite

Purpose: Lyme disease has become an increasingly important global public health concern. Method: A narrative review was conducted and designed to present a broad perspective on Lyme disease, and describe its history and development in terms of clinical care and public health implications. A structured literature search was conducted based on the question; what is currently known about Lyme disease? Results: The narrative review is presented in chronological order in terms of a summary of the history of Lyme disease, the complexities of clinical diagnosis, the problematic interpretation of serologic testing, the conflicting guidelines for diagnosis, treatment and management of chronic Lyme, and benefits of antibiotic treatment. Conclusion: Despite growing global incidence of the Lyme disease, treatment has not attracted pharmaceutical investment, and the evidence base and international guidelines for treatment and management of chronic Lyme continue to be conflicting and controversial. The challenges of this immune mediated tick borne disease for public health policy and clinical practice are summarised, alongside directions for future research.

show abstract

“…The prophylactic application of an antibiotic cream is also controversial. Animal studies with azithromycin cream reveal a good prophylactic efficacy [ 169 ], [ 170 ]. Placebo-controlled studies on the effectiveness in humans have yet to be published.…”

Section: Prophylaxismentioning

confidence: 99%